Why the study?
Does stenting combined with abciximab reduce the 6-month composite of death, MI, or TVR compared to stenting with placebo or balloon angioplasty with abciximab in diabetic patients?
RCT (n=491)
Yes
Does stenting combined with abciximab reduce the 6-month composite of death, MI, or TVR compared to stenting with placebo or balloon angioplasty with abciximab in diabetic patients?
The combination of stenting and abciximab significantly reduces 6-month rates of death, MI, and TVR in diabetic patients compared to stenting alone or balloon angioplasty with abciximab.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Marso et al. (1999) conducted an RCT in Diabetes Mellitus (n=491). Stent-abciximab vs. Stent-placebo and balloon angioplasty-abciximab was evaluated on Combined 6-month death, myocardial infarction (MI), or target-vessel revascularization (TVR) (p=0.005).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: